The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.General Information About Ovarian Epithelial Cancer Updated statistics with estimated new cases and deaths for 2013 (cited American Cancer Society as reference 1).This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
Related Summaries Note: Other PDQ summaries containing information related to ovarian epithelial cancer include the following: Genetics of Breast and Ovarian Cancer Ovarian Cancer Screening Ovarian Cancer Prevention Unusual Cancers of Childhood Statistics Note: Estimated new cases and deaths from ovarian cancer in the United States in 2010:[ 1 ] New cases: 21,880. Deaths: 13,850. Note: Some ...
In the absence of obvious metastatic disease, accurate staging of germ cell tumors of the ovary requires laparotomy with careful examination of the following:Entire diaphragm.Both paracolic gutters.Pelvic nodes on the side of the ovarian tumor.The para-aortic lymph nodes.The omentum.The contralateral ovary should be carefully examined and biopsied if necessary. Ascitic fluid should be examined cytologically. If ascites is not present, it is important to obtain peritoneal washings before the tumor is manipulated. In patients with dysgerminoma, lymphangiography or computed tomography is indicated if the pelvic and para-aortic lymph nodes were not carefully examined at the time of surgery. Although not required for formal staging, it is desirable to obtain serum levels of alpha fetoprotein (AFP) and human chorionic gonadotropin (hCG) as soon as the diagnosis is established since persistence of these markers in the serum after surgery indicates unresected tumor.Definitions: FIGOThe
Note: Separate PDQ summaries on Ovarian Cancer Prevention; Ovarian Epithelial Cancer Treatment; Ovarian Germ Cell Tumor Treatment; and Ovarian Low Malignant Potential Tumor Treatment are also available. Evidence of Benefit or Lack of Benefit Associated with ScreeningSingle-threshold cancer antigen 125 (CA-125) levels and transvaginal ultrasound (TVU)There is solid evidence to indicate that routine screening for ovarian cancer with the serum marker CA-125 and TVU does not result in a decrease in mortality from ovarian cancer.Magnitude of Effect: No reduction in mortalityStudy Design: Evidence obtained from one randomized controlled trial.Internal Validity: Good.Consistency: One trial has evaluated the impact on mortality from ovarian cancer.External Validity: Good.Statement of HarmsBased on solid evidence, routine screening for ovarian cancer results in false-positive test results among 9.6% of those screened; of those with false-positive results who had surgery, the complication rate
Purpose of This SummaryThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about ovarian cancer prevention. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.Reviewers and UpdatesThis summary is reviewed regularly and updated as necessary by the PDQ Screening and Prevention Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). Board members review recently published articles each month to determine whether an article should:be discussed at a meeting,be cited with text, orreplace or update an existing article that is already cited.Changes to the summaries are made through a consensus process in
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Ovarian Cancer Screening
DysgerminomasStandard treatment options:Total abdominal hysterectomy and bilateral salpingo-oophorectomy with adjuvant chemotherapy.Unilateral salpingo-oophorectomy with adjuvant chemotherapy.For patients with stage IV dysgerminoma, total abdominal hysterectomy and bilateral salpingo-oophorectomy is recommended with removal of as much gross tumor in the abdomen and pelvis as can be done safely without resection of portions of the urinary tract or large segments of small or large bowel, although unilateral salpingo-oophorectomy should be considered in patients who wish to preserve fertility.[1,2] Chemotherapy with bleomycin/etoposide/cisplatin (BEP) can cure the majority of such patients. Stage IV dysgerminoma is not treated with radiation therapy, but rather with chemotherapy, preferably with three to four courses of cisplatin-containing combination chemotherapy such as BEP. A second-look operation following treatment is rarely beneficial. (Refer to the PDQ summary on Sexuality and
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Ovarian Cancer Prevention
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Ovarian Epithelial Cancer Treatment